Keywords
Treatment
New amphetamine derivatives
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Discuss the new amphetamine derivatives used to treat Attention Deficit Hyperactivity Disorder (ADHD), highlighting positive aspects and weaknesses. Bibliographic review: ADHD, a neurodevelopmental syndrome marked by inattention, hyperactivity and impulsivity, has amphetamines as the first choice of pharmacological treatment, such as amphetamine, dextroamphetamine, lisdexamfetamine and methylphenidate. Different formulations of these drugs, from oral suspensions, prolonged-release chewable tablets and transdermal patches, are some of the new treatment options. Final considerations: The preference for amphetamines in adults stands out, while methylphenidate is more suitable for children and adolescents, although lisdexamfetamine is also an important option. New extended-release formulations, such as oral suspensions and tablets, have demonstrated efficacy and safety, offering more convenient therapeutic options, with better chances of adherence and less potential for abuse, with emphasis also on use in the form of a transdermal patch. However, adverse events and weaknesses must be considered in therapeutic decisions. And even with the important advances in this pharmacotherapy, some patients remain without an adequate therapeutic response, and it is important to continue studies and develop medications for treatment of different ADHD phenotypes, allowing better choice and more rational treatment for patients.
References
ABDA. Associação Brasileira do Déficit de Atenção. 2015. Disponível em: http://www.tdah.org.br/ Acesso em: 13 set. 2023.
ADLER LA, et al. Post hoc responder and remission analyses from two studies of SHP465 mixed amphetamine salts extended-release among adults with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2020; 30(7), 427-438.
AHLBERG R, et al. Associations Between Attention-Deficit/Hyperactivity Disorder (ADHD), ADHD Medication, and Shorter Height: A Quasi-experimental and Family-Based Study. Journal of the American Academy of Child & Adolescent Psychiatry, 2023; 62(12): 1316-1325.
AVELAR AJ, et al. Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms. Journal of neurochemistry, 2013; 125(3): 373-385.
BRUMBAUGH S, et al. Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: an observational cohort study. EClinicalMedicine, 2022; 50: 101524.
CHILDRESS AC, et al. A post hoc comparison of prior ADHD medication dose and optimized delayed-release and extended-release methylphenidate dose in a pivotal phase III trial. Clinical Therapeutics, 2020; 42(12), 2332-2340.
CHILDRESS AC, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings. Journal of child and adolescent psychopharmacology, 2020; 30(1): 2-14.
CHILDRESS AC, et al. Early-onset efficacy and safety pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2019; 29(1): 2-8.
CHILDRESS AC, et al. Gender effects in the efficacy of racemic amphetamine sulfate in children with attention-deficit/hyperactivity disorder. Advances in Therapy, 2019; 36: 1370-1387.
CHILDRESS AC, et al. Long-term treatment with extended-release methylphenidate treatment in children aged 4 to< 6 years. Journal of the American Academy of Child & Adolescent Psychiatry, 2022; 61(1): 80-92.
CHILDRESS AC, et al. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above. Expert Opinion on Drug Delivery, 2018; 15(12): 1263-1270.
CHILDRESS AC, et al.The efficacy and safety of evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: A multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of child and adolescent psychopharmacology, 2015; 25(5): 402-414.
CHILDRESS AC. Methylphenidate HCL for the treatment of ADHD in children and adolescents. Expert opinion on pharmacotherapy, 2016; 17(8): 1171-1178.
CHILDRESS AE, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 2018; 28: 306–313.
CORTESE S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 2018; 5(9): 727-738.
CORTESE S. Pharmacologic Treatment os Attention Deficit-Hyperactivity Disorder. N Engl J Med. 2020; 383(11): 1050-1056.
CUTLER AJ, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry, 2022; 83(5): 41875.
DALSGAARD S, et al. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood—a naturalistic long-term follow-up study. Addictive behaviors, 2014; 39(1): 325-328.
FARAONE SV, et al. Attention-deficit/hyperactivity disorder. Nature reviews Disease primers, 2015; 1: 15020.
FARAONE SV, et al. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: Impact on the family. Journal of child and adolescent psychopharmacology, 2017; 27(8): 715-722.
FARAONE SV, et al. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of Child and Adolescent Psychopharmacology, 2023; 33(1): 14-19.
FARAONE SV, et al. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 2021; 128: 789-818.
FAYYAD J, et al. The descriptive epidemiology of DSM-IV adult ADHD in the world health organization world mental health surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017; 9: 47-65.
FINDLING RL et al. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS drugs, 2014; 28: 217-228.
FRAMPTON JE. Lisdexamfetamine dimesylate: a review in paediatric ADHD. Drugs, 2018; 78: 1025-1036.
FRANKE B, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 2018; 28(10): 1059-1088.
FRICK G, et al. Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial. Journal of Attention Disorders, 2020; 24(3): 402-413.
HEAL DJ, et al. Amphetamine, past and present–a pharmacological and clinical perspective. Journal of psychopharmacology, 2013; 27(6): 479-496.
ILIC I, ILIC M. Global incidence of attention deficit/hyperactivity disorder among children. Biology and Life Sciences Forum. MDPI, 2022; 1(6).
KIM JH, et al. Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. The Lancet Psychiatry. 2020; 7(11): 955–70.
KOOIJ JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European psychiatry, 2019; 56(1): 14-34.
MALTEZOS S, et al. Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. Transl. Psychiatry, 2014; 4: e373.
NGAN M, et al. Risk factors and impact of ADHD on children with recent Onset Epilepsy. HK J Paediatr (new series). 2019; 24(2): 65.
NICE. National Institute for Health and Care Excellence Attention deficit hyperactivity disorder: diagnosis and management. Disponível em: https://www.nice.org.uk/guidance/ng87. Acesso em 25 out. 2023.
PARDO A, et al. Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD. Drug Design, Development and Therapy, 2021; 2979-2985.
QUELCH DR, et al. Imaging endogenous opioid peptide release with [11C] carfentanil and [3H] diprenorphine: influence of agonist-induced internalization. Journal of Cerebral Blood Flow & Metabolism, 2014; 34(10): 1604-1612.
SAGVOLDEN T, Xu T. l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behavioral and Brain Functions, 2008; 4(1): 1-12.
SURMAN CB, et al. post-hoc analyses of the effects of baseline sleep quality on SHP465 mixed amphetamine salts extended-release treatment response in adults with attention-deficit/hyperactivity disorder. CNS drugs, 2019; 33: 695-706.
WILLOUGHBY MT. Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations. J Child Psychol Psychiatry. 2003; 44: 88-106.
ZAHED G, et al. The Effect of Long-Acting Methylphenidate and Modafinil on Attention and Impulsivity of Children with ADHD using a Continuous Performance Test: A Comparative Study. Iranian Journal of Child Neurology, 2022; 16(3): 67.